For example, carriers with DNMT3A, TET2, and ASXL1 mutations had a 1.7-2.0 times risk of CAD compared to a 12.1 times risk of CAD in JAK2 V617F mutation carriers.16 This evidence concerns the gene TET2 and coronary artery disorder.